Kopran

Mumbai, India Founded: 1997 • Age: 29 yrs Listed
Pharmaceutical Company manufacturing a range of products
Request Access
Report Incorrect Data
Page last updated

About Kopran

Kopran is a publicly listed company based in Mumbai (India) founded in 1997. Pharmaceutical Company manufacturing a range of products. The company has 196 employees. Its Indian entity Kopran Limited reported revenue of ₹682 Cr. Its focus areas include Biopharma Outsourcing, CDMO and Small Molecules & Peptides. Similar companies include Aurobindo Pharma, Indoco Remedies and Concord Biotech.

Company details

Kopran was founded in 1997 and is headquartered in Mumbai, India. Operations focus on the pharmaceutical sector, where finished dosage forms are produced, active pharmaceutical ingredients are researched and developed, and consumer healthcare items are handled. Coverage extends to therapeutic categories such as anthelmintics, antibiotics, cardiovascular treatments, and gastroenterology solutions. More than 500 products form the portfolio, while formulation development services are offered for regulated markets.

  • Headquarters Mumbai, India
  • Employees 196
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Website kopran.com
  • Social LinkedIn
  • Legal Name Kopran Limited
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹1,255 Cr

    KOPRAN · NSE

  • Share Price
    ₹263.89

    +1.59% today

  • Revenue
    ₹681 Cr

    FY 2025-26 · +8.2% YoY

  • EBITDA
    ₹61.95 Cr

    Margin 9.1%

  • Net Profit
    ₹25.73 Cr

    FY 2025-26 · -33.2% YoY

  • P/E (TTM)
    31.9x

    P/B 2.4x

  • ROE
    4.9%

    ROCE 6.5%

  • Debt / Equity
    0.29

    Interest cover 23.5x

  • Employee Count
    196

Board of directors of Kopran Limited (Kopran)

Kopran Limited is the primary company behind Kopran. The boards of the 4 registered companies of Kopran currently have 15 directors; the longest-serving is Somani Surendra, appointed in 1997. 52 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Somani Surendra
DIN 00600860
Managing Director11 Jun 199729 yrs 5 moKopran Limited
Prashant Gopal Mantri
DIN 02160348
Director09 Jan 201214 yrs 10 moKopran Lifestyle Limited
Suhrid Susheel Somani
DIN 00217379
Director09 Jan 201214 yrs 10 moKopran Lifestyle Limited
Adarsh Rajendra Somani
DIN 00192609
Director23 Feb 201214 yrs 8 moKopran Lifestyle Limited, Kopran Laboratories Limited
Vandana Surendra Somani
DIN 01218254
Director18 Feb 201511 yrs 8 moKopran Research Laboratories Limited
Chandra Mohan Singhi
DIN 01793293
Whole-time director24 Jun 201511 yrs 4 moKopran Research Laboratories Limited
Sunita Banerji
DIN 02476075
Director01 Mar 201610 yrs 8 moKopran Research Laboratories Limited
Rakesh Arunkumar Doshi
DIN 00359832
Director14 Nov 20178 yrs 11 moKopran Research Laboratories Limited
Varun Surendra Somani
DIN 00015384
Director29 May 20188 yrs 5 moKopran Limited, Kopran Laboratories Limited
Mamta Ashok Biyani
DIN 01850136
Director08 May 20197 yrs 6 moKopran Limited, Kopran Research Laboratories Limited
Narayan Tulsiram Atal
DIN 00237626
Director08 May 20197 yrs 6 moKopran Limited
Surendran Nair
DIN 06509470
Director02 Aug 20242 yrs 3 moKopran Laboratories Limited
Rajiv Bafna Tejraj
DIN 01391556
Director02 Aug 20242 yrs 3 moKopran Laboratories Limited
Chandresh Gunvant Gandhi
DIN 00707947
Director29 Jul 20251 yr 3 moKopran Limited
Namrata Varun Somani
DIN 07095595
Additional Director19 May 20265 moKopran Limited, Kopran Laboratories Limited

People of Kopran

2 people are tracked at Kopran (2 in leadership); the tracked headcount is 196.

NameRoleGroup
Upendra Singh
PresidentLeadership
Susheel G Somani
Managing DirectorLeadership
Premium access

Complete people profiles for Kopran

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Kopran

Kopran is a publicly listed company on the NSE with ticker symbol KOPRAN in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date02 Jan 2018
  • Listed onBSE: 524280
  • Listed entityKopran Limited
  • Exchange sectorHealth technology
  • ISININE082A01010
  • Share price₹283.95 (+7.41% on the day) · 2026-10-14
  • Market capitalisation₹1,276 Cr
  • Price to earnings54.9
  • EPS (diluted, trailing year)₹5.17
  • Dividend yield1.14%
  • Volume (last session)951,483

Financials of Kopran

Exchange-reported figures of Kopran Limited, the listed company behind Kopran (NSE: KOPRAN).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹681 Cr
+8.2% YoY
EBITDA
₹61.95 Cr
-15.0% YoY
Profit After Tax
₹25.73 Cr
-33.2% YoY
Net Worth
₹530 Cr
+2.3% YoY
Total Assets
₹692 Cr
+2.2% YoY
Total Debt
₹153 Cr
+3.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue681630615551478492360
Revenue growth+8.2%+2.4%+11.5%+15.4%-2.9%+36.8%-
EBITDA61.9572.8874.4151.7987.3881.7746.14
EBITDA margin+9.1%+11.6%+12.1%+9.4%+18.3%+16.6%+12.8%
Profit before tax34.3651.9367.5436.0781.7683.3328.28
Net profit25.7338.5450.9527.2461.0161.6921.50
Net profit margin+3.8%+6.1%+8.3%+4.9%+12.8%+12.5%+6.0%
EPS (₹)5.337.9810.575.6512.6614.244.86
Balance sheet
Total assets692677599523509319285
Net worth530518491439426245190
Total debt15314899.2375.2474.5566.3188.28
Cash & bank7.2225.8614.2012.5857.136.904.75
Net working capital316352318279319161139
Cash flow
Cash from operations66.7541.9443.2634.02(33.48)59.9531.00
Cash from investing(64.60)(56.43)(43.55)(12.65)(84.42)(25.28)(12.52)
Cash from financing(20.94)25.870.99(19.84)123(34.57)(18.06)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue211154234194118135172166
Revenue growth (YoY)+79.2%+13.9%+35.8%+16.9%-22.2%-3.0%--
Other income0.622.050.090.070.032.563.260.17
EBITDA15.4115.8032.9517.76(5.28)14.1317.0819.84
EBITDA margin+7.3%+10.3%+14.1%+9.1%-4.5%+10.4%+9.9%+11.9%
Depreciation5.895.774.524.424.284.263.874.00
Interest4.253.283.172.672.092.542.772.16
Profit before tax5.898.8025.3510.74(11.62)9.8913.7013.85
Tax1.502.106.481.40(1.70)2.444.033.46
Net profit4.396.7018.879.34(9.92)7.459.6710.39
EPS (₹)0.911.393.911.93(2.06)1.542.002.15
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue306271337273205223179
Revenue growth+12.8%-19.7%+23.6%+33.5%-8.2%+24.3%-
EBITDA47.5738.6536.9327.9015.4330.2023.17
EBITDA margin+15.6%+14.3%+10.9%+10.2%+7.5%+13.6%+12.9%
Profit before tax40.3935.7844.5236.9116.1932.7015.73
Net profit30.3926.8434.6531.2511.7723.4711.26
Net profit margin+9.9%+9.9%+10.3%+11.4%+5.8%+10.5%+6.3%
EPS (₹)6.305.567.186.482.445.432.59
Balance sheet
Total assets498482444428420266279
Net worth448431417396379247230
Total debt46.3645.3122.7127.8836.9015.7245.72
Cash & bank2.1821.027.422.592.553.221.15
Net working capital13714712411511055.8866.42
Cash flow
Cash from operations29.6623.3034.9616.87(37.80)48.779.97
Cash from investing(30.08)(15.41)(6.27)10.05(100)(8.51)0.63
Cash from financing(18.53)5.64(24.08)(26.13)138(40.14)(10.60)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue87.1262.7611893.8842.3951.3375.9471.94
Revenue growth (YoY)+105.5%+22.3%+55.4%+30.5%-42.4%+3.5%--
Other income0.862.911.000.320.321.801.920.75
Total expenses76.8054.3091.4576.2045.6046.2663.6560.54
EBITDA10.328.4626.5917.68(3.21)5.0712.2911.40
EBITDA margin+11.8%+13.5%+22.5%+18.8%-7.6%+9.9%+16.2%+15.8%
Depreciation1.391.351.341.251.161.221.241.33
Interest1.391.241.171.160.831.041.260.99
Profit before tax8.408.7825.0815.59(4.88)4.6111.719.83
Tax2.132.066.333.45(0.88)1.093.112.42

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 11 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue211154234194118135172166
Revenue growth (YoY)+79.2%+13.9%+35.8%+16.9%-22.2%-3.0%--
Other income0.622.050.090.070.032.563.260.17
EBITDA15.4115.8032.9517.76(5.28)14.1317.0819.84
EBITDA margin+7.3%+10.3%+14.1%+9.1%-4.5%+10.4%+9.9%+11.9%
Depreciation5.895.774.524.424.284.263.874.00
Interest4.253.283.172.672.092.542.772.16
Profit before tax5.898.8025.3510.74(11.62)9.8913.7013.85
Tax1.502.106.481.40(1.70)2.444.033.46
Net profit4.396.7018.879.34(9.92)7.459.6710.39
EPS (₹)0.911.393.911.93(2.06)1.542.002.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue681630615551478492360
Revenue growth+8.2%+2.4%+11.5%+15.4%-2.9%+36.8%-
Other income0.353.9814.613.0710.6017.990.63
Total expenses619557540499390410313
Employee cost65.2160.5452.2849.9543.2737.1636.85
EBITDA61.9572.8874.4151.7987.3881.7746.14
EBITDA margin+9.1%+11.6%+12.1%+9.4%+18.3%+16.6%+12.8%
Depreciation17.4715.5912.8912.7111.1010.199.58
Interest10.479.348.596.085.126.248.91
Profit before tax34.3651.9367.5436.0781.7683.3328.28
Tax8.6313.3916.598.8320.7521.737.27
Net profit25.7338.5450.9527.2461.0161.6921.50
Net profit margin+3.8%+6.1%+8.3%+4.9%+12.8%+12.5%+6.0%
EPS (₹)5.337.9810.575.6512.6614.244.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital48.2948.2948.2148.2148.2143.2543.25
Reserves & surplus482470443391378202146
Shareholders' funds (net worth)530518491439426245190
Minority interest0.000.000.000.000.000.000.00
Secured loans13013383.0557.9855.6461.3362.88
Unsecured loans22.7214.4716.1817.2618.914.9825.40
Total debt15314899.2375.2474.5566.3188.28
Total liabilities692677599523509319285
Assets
Gross block461306263234207157146
Net block346208182165151112111
Capital work in progress24.7911396.5969.5835.5542.8930.24
Investments0.060.060.060.060.060.050.02
Inventories16416913813115010088.50
Sundry debtors26321521216312712092.81
Cash & bank balances7.2225.8614.2012.5857.136.904.75
Loans & advances89.0999.5389.0293.3280.4449.9736.55
Total current assets523510454399415277223
Total current liabilities20715813612095.8011683.61
Net working capital316352318279319161139
Total assets692677599523509319285
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash19.478.097.405.870.940.830.41
Net cash from operating activities66.7541.9443.2634.02(33.48)59.9531.00
Net cash from investing activities(64.60)(56.43)(43.55)(12.65)(84.42)(25.28)(12.52)
Net cash from financing activities(20.94)25.870.99(19.84)123(34.57)(18.06)
Net change in cash(18.79)11.380.691.534.930.100.42
Closing cash7.2225.8614.2012.5857.136.904.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+8.2%+2.4%+11.5%+15.4%-2.9%+36.8%-
EBITDA growth-15.0%-2.1%+43.7%-40.7%+6.9%+77.2%-
PBT growth-33.8%-23.1%+87.3%-55.9%-1.9%+194.7%-10.7%
Net income growth-33.2%-24.4%+87.0%-55.4%-1.1%+186.9%-
Revenue CAGR (3Y)+7.3%+9.7%+7.7%+15.3%+10.1%+16.2%+5.1%
EBITDA CAGR (3Y)+6.2%-5.9%-3.1%+3.9%+23.6%+39.1%+8.6%
Profitability & leverage
Net income margin+3.8%+6.1%+8.3%+4.9%+12.8%+12.5%+5.8%
Return on capital employed+6.6%+9.6%+13.6%+8.2%+21.0%+29.6%+12.8%
Return on net worth+4.9%+7.6%+11.0%+6.3%+18.2%+28.3%+11.1%
Debt / equity0.290.240.190.170.210.360.49
Long-term debt / equity0.030.030.030.040.050.110.16
Interest cover23.5416.3013.9615.566.718.7224.37
Efficiency & per share
Fixed asset turnover1.782.212.472.502.623.242.53
Inventory turnover4.084.094.573.933.825.224.44
Debtors turnover2.852.953.283.803.864.624.01
EPS (₹)5.337.9810.575.6512.6614.244.86
Dividend per share (₹)3.003.003.003.003.003.000.00
Book value per share (₹)109.82107.35101.9091.1188.4056.6543.86
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue87.1262.7611893.8842.3951.3375.9471.94
Revenue growth (YoY)+105.5%+22.3%+55.4%+30.5%-42.4%+3.5%--
Other income0.862.911.000.320.321.801.920.75
Total expenses76.8054.3091.4576.2045.6046.2663.6560.54
EBITDA10.328.4626.5917.68(3.21)5.0712.2911.40
EBITDA margin+11.8%+13.5%+22.5%+18.8%-7.6%+9.9%+16.2%+15.8%
Depreciation1.391.351.341.251.161.221.241.33
Interest1.391.241.171.160.831.041.260.99
Profit before tax8.408.7825.0815.59(4.88)4.6111.719.83
Tax2.132.066.333.45(0.88)1.093.112.42
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue306271337273205223179
Revenue growth+12.8%-19.7%+23.6%+33.5%-8.2%+24.3%-
Other income2.005.9016.7116.098.0310.411.99
Total expenses258232301245189193156
Employee cost32.9430.0225.6125.1521.0518.3420.02
EBITDA47.5738.6536.9327.9015.4330.2023.17
EBITDA margin+15.6%+14.3%+10.9%+10.2%+7.5%+13.6%+12.9%
Depreciation4.985.004.624.414.324.103.47
Interest4.203.774.502.672.953.815.96
Profit before tax40.3935.7844.5236.9116.1932.7015.73
Tax10.008.949.885.664.429.244.51
Net profit30.3926.8434.6531.2511.7723.4711.26
Net profit margin+9.9%+9.9%+10.3%+11.4%+5.8%+10.5%+6.3%
EPS (₹)6.305.567.186.482.445.432.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital48.2948.2948.2148.2148.2143.2543.25
Reserves & surplus400383369347331204186
Shareholders' funds (net worth)448431417396379247230
Secured loans44.3643.3120.7125.8826.8212.7214.40
Unsecured loans2.002.002.002.0010.083.0031.32
Total debt46.3645.3122.7127.8836.9015.7245.72
Total liabilities498482444428420266279
Assets
Gross block12296.6782.4673.1767.6364.6056.00
Net block81.8861.4552.0247.3546.2247.4442.95
Capital work in progress7.597.444.703.533.102.827.07
Investments265263261260259159158
Inventories65.8555.7549.4947.6041.5127.5041.17
Sundry debtors13391.9287.8083.8159.1349.4642.48
Cash & bank balances2.1821.027.422.592.553.221.15
Loans & advances39.6440.3642.9956.4048.1130.9229.44
Total current assets240209188190151111114
Total current liabilities10461.5764.0675.2941.4355.2247.82
Net working capital13714712411511055.8866.42
Total assets498482444428420266279
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash19.185.651.040.250.320.210.21
Net cash from operating activities29.6623.3034.9616.87(37.80)48.779.97
Net cash from investing activities(30.08)(15.41)(6.27)10.05(100)(8.51)0.63
Net cash from financing activities(18.53)5.64(24.08)(26.13)138(40.14)(10.60)
Net change in cash(18.95)13.534.610.79(0.07)0.120.00
Closing cash2.1821.027.422.592.553.221.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.8%-19.7%+23.6%+33.5%-8.2%+24.3%-
EBITDA growth+23.1%+4.7%+32.4%+80.8%-48.9%+30.3%-
PBT growth+12.9%-19.6%+20.6%+128.0%-50.5%+107.9%-9.4%
Net income growth+13.2%-22.5%+10.9%+165.5%-49.9%+108.4%-
Revenue CAGR (3Y)+3.8%+9.8%+14.8%+15.1%+1.3%+13.2%-0.4%
EBITDA CAGR (3Y)+19.5%+35.8%+6.9%+6.4%-12.2%+49.9%+10.1%
Profitability & leverage
Net income margin+9.9%+9.9%+10.3%+11.4%+5.8%+10.5%+6.3%
Return on capital employed+9.1%+8.5%+11.2%+9.3%+5.6%+13.4%+7.9%
Return on net worth+6.9%+6.3%+8.5%+8.1%+3.8%+9.9%+5.0%
Debt / equity0.100.080.060.080.080.130.20
Long-term debt / equity0.000.000.000.000.000.010.04
Interest cover9.8611.2013.9311.3726.5514.6030.25
Efficiency & per share
Fixed asset turnover2.803.034.343.883.093.703.34
Inventory turnover5.035.156.956.135.936.495.40
Debtors turnover2.723.023.933.823.774.854.12
EPS (₹)6.305.567.186.482.445.432.59
Dividend per share (₹)3.003.003.003.003.003.000.00
Book value per share (₹)92.7589.3586.4782.0578.5657.0753.10

Similar companies to Kopran

Kopran has 3 listed similar companies in our database. They include Aurobindo Pharma, Indoco Remedies and Concord Biotech.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Aurobindo Pharma
aurobindo.com1986Hyderabad, India1,010
Generic biocatalytic solutions are provided for pharmaceutical applications.
Indoco Remedies
indoco.com1947Mumbai, India6,291
APIs manufacturing and formulation services are provided in therapeutic segments.
Concord Biotech
concordbiotech.com2000Ahmedabad, India1,598
APIs and enzymes are manufactured through fermentation by the CDMO.
Premium access

Detailed similar companies of Kopran

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Kopran

The website of Kopran (kopran.com) receives about 3.7K visits a month and ranks #4,907,793 among all websites worldwide, #5,730 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    3.7K

    ▲ 2% vs previous month

  • Unique visitors
    1.7K

    per month

  • Global rank
    #4,907,793

    among all websites

  • Category rank
    #5,730

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Kopran. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Ajanta Pharma
ajantapharma.com
100%
20.1K#1,412,069View details
CEL-SCI
cel-sci.com
84%
3.2K#5,603,385View details
Piramal Enterprises
piramalenterprises.com
84%
6.6K#2,681,887View details
Khandelwal Laboratories
khandelwallab.com
59%
6.5K#1,877,524View details
Medindia
medindia.net
34%
828.7K#78,367View details
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 6 similar websites and full traffic analytics for Kopran

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 6 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Kopran (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Kopran

KOPRAN: Q2 CONS NET PROFIT 44M RUPEES VS LOSS 100M (YOY)
Exchange Update • 8 days ago
KOPRAN: Q2 EBITDA GAIN 154M RUPEES VS LOSS 52M (YOY); Q2 EBITDA MARGIN 7.3%
Exchange Update • 8 days ago
KOPRAN: Q2 REVENUE 2.1B RUPEES VS 1.2B (YOY)
Exchange Update • 8 days ago
KOPRAN: Co Reports Successful Inspection Of Khopoli Facility With No Major Concerns.
Exchange Update • 20 days ago
Kopran June-Quarter Consol Profit 67 Million Rupees
Reuters • 3 months ago
Kopran March-Quarter Consol Net Profit 188.7 Million Rupees
Reuters • 5 months ago
Kopran Flags Cyber-Attack At Its Khopoli Factory
Reuters • 8 months ago
Kopran Dec-Quarter Consol Profit 93.4 Million Rupees
Reuters • 9 months ago
Kopran Says Maharashtra Tax Authorities Initiate Search At Mumbai Office
Reuters • 9 months ago
Kopran Sept-Quarter Consol Loss 99.2 Million Rupees
Reuters • 12 months ago
Premium access

Complete news archive for Kopran

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kopran

Kopran was founded in 1997.

Kopran is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Kopran has 196 employees.

The primary company behind Kopran, Kopran Limited, reported revenue of ₹682 Cr for FY 2026, up 8% year on year.

Kopran was founded in 1997 and is headquartered in Mumbai, India. Operations focus on the pharmaceutical sector, where finished dosage forms are produced, active pharmaceutical ingredients are researched and developed, and consumer healthcare items are handled. Coverage extends to therapeutic categories such as anthelmintics, antibiotics, cardiovascular treatments, and gastroenterology solutions. More than 500 products form the portfolio, while formulation development services are offered for regulated markets.

Kopran's top competitors include Concord Biotech, Indoco Remedies and Aurobindo Pharma.

Yes, Kopran is publicly traded on NSE under the ticker symbol KOPRAN.

Kopran is associated with 4 legal entities: Kopran Limited, Kopran Lifestyle Limited, Kopran Research Laboratories Limited and others.

The legal entities of Kopran currently have 19 directors, including Mamta Ashok Biyani, Narayan Tulsiram Atal, Somani Surendra and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available